Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | HPRT1 | P00492 | 8/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PNP | P00491 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8708627 | 0.93 | FDPS (0.59) | FDPSHDAC1HDAC6FGFR1SLC22A6 | |
| SCHEMBL3054581 | 0.86 | FGFR1 (0.60) | FDPSHDAC1HDAC6FGFR1SLC22A6 | |
| SCHEMBL9124001 | 0.78 | FDPS (0.50) | FDPSHDAC1HDAC6FGFR1SLC22A6 | |
| SCHEMBL6935229 | 0.78 | FDPS (0.49) | FDPSHDAC1HDAC6ENPP1LTA4H | |
| SCHEMBL8525122 | 0.78 | FDPS (0.67) | FDPSHDAC1HDAC6CYP3A4 | |
| SCHEMBL8525119 | 0.78 | FDPS (0.67) | FDPSHDAC1HDAC6CYP3A4 | |
| SCHEMBL3976006 | 0.77 | FDPS (1.00) | FDPSHDAC1HDAC6LTA4HHPRT1 | |
| SCHEMBL8444477 | 0.75 | FDPS (0.46) | FDPSHDAC1HDAC6ENPP1LTA4H | |
| SCHEMBL23398227 | 0.74 | FDPS (0.50) | FDPSHDAC1HDAC6LTA4HCYP3A4 | |
| SCHEMBL9516044 | 0.72 | FDPS (0.59) | FDPSHDAC1HDAC6LTA4HCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754718-B2 | Antiviral helioxanthin analogs | YALE UNIVERSITY (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080167353-A1 | Novel Antiviral Helioxanthin Analogs | YALE UNIVERSITY (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2005107742-A1 | NOVEL ANTIVIRAL HELIOXANTHIN ANALOGS | YALE UNIVERSITY (US) | 2005-11-17 | — | — | WO | disclosed |
| US-6306899-B1 | VIRICIDES | YALE UNIVERSITY | 2001-10-23 | — | — | US | disclosed |
| EP-1107961-A1 | INHIBITION AND TREATMENT OF HEPATITIS B VIRUS AND FLAVIVIRUS BY HELIOXANTHIN AND ITS ANALOGS | YALE UNIVERSITY (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000010991-A1 | INHIBITION AND TREATMENT OF HEPATITIS B VIRUS AND FLAVIVIRUS BY HELIOXANTHIN AND ITS ANALOGS | YALE UNIVERSITY (US) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167353-A1 | Novel Antiviral Helioxanthin Analogs | HAVCR2, ZC3HAV1, DHX35 | FDPS 1843/4885HDAC1 438/4885HDAC6 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.